Angelini Ventures

Corporate venture capital fund of the Angelini group investing in biotechs.

Profile being verified

Stage
Series B to Series C across recorded rounds
Ticket
Ticket sizes not disclosed; recorded rounds of CHF 26 M to USD 135 M
Location
Not specified
Tracked rounds
2

What they look for

Co-led the Series B extension of NUCLIDIUM (Regina Hodits, managing director). It has followed Nouscom since its Series C and is participating in its new round, which Angelini Industries is joining via Angelini Investments.

Recent investments

Recorded Swiss rounds: NUCLIDIUM (Series B, CHF 26 M, May 2026, co-lead), Nouscom (Series C, USD 135 M, October 2026).

Rounds tracked by FundSwiss